Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer

Boston Scientific Corporation announced the appointment of Joseph M. Fitzgerald as executive vice president and chief operating officer, effective January 1, 2027. Fitzgerald will oversee the company's global operations, business units and regions, succeeding the current leadership structure. The appointment reflects the company's growth and expanding portfolio, requiring a more structured operational approach. Fitzgerald brings deep business knowledge and a strong track record of execution to the role.

The company will establish three reportable segments—Interventional Therapies, Rhythm Solutions and MedSurg—effective January 1, 2027. This reorganization aims to enable faster decision-making and strategic investment allocation across the portfolio. The new structure is designed to support long-term growth priorities while maintaining close customer and patient focus. Boston Scientific emphasized the scale and breadth of its business as a driver for these changes.

Lance Bates will lead the Interventional Therapies segment, which will include the Penumbra business following the anticipated acquisition. Nick Spadea-Anello will lead the Rhythm Solutions segment, while Stephen Morse will oversee the MedSurg and Asia Pacific segment. Each segment leader will report directly to Fitzgerald, ensuring clear accountability and alignment with the company's strategic goals.

Fitzgerald currently serves as executive vice president and group president, Cardiovascular, at Boston Scientific. Under his leadership, the company has expanded its portfolio through innovation, strategic investments and commercial execution. His appointment to COO follows a period of significant portfolio growth and operational strengthening, positioning him to lead the company's next phase of development.